Search Results

In October 2023, Sino Biological, Inc. opened its Center for Bioprocessing (C4B) in Houston, Texas. The C4B represents a considerable global expansion of the company’s contract research service capabilities.

Sino Biological, Inc. has successfully concluded the acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), specializing in...

Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc.

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields

Sino Biological, Inc. is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.

Sino Biological, Inc.(“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.